ERBB2 and breast carcinoma: The present study suggests that these Trk inhibitors, such as the GNF-5837 that we have used here, should also be evaluated for HER2-positive breast cancer, particularly for cases that are resistant to current therapeutic approaches, as they may represent future candidates of clinical importance.